New CLEAR Outcomes data: Bempedoic acid cuts risk for recurrent CV events

A prespecified analysis of the CLEAR Outcomes trial shows that the benefits of bempedoic acid extend to patients with recurrent CV events, including a total reduction in MI risk of 31% vs. placebo.
As Healio previously reported, data from the CLEAR Outcomes trial demonstrated bempedoic acid (Nexletol, Esperion Therapeutics) reduced risk for major CV events by 13% compared with placebo, including a 23% lower risk for MI, among adults with a history of CVD or at high risk deemed statin intolerant. In a new analysis, researchers assessed the impact of bempedoic acid on the total incidence of

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart